Form 4: TScan Therapeutics Executive Zoran Zdraveski Reports Stock Option Grants
SEC Form 4 Filing
Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics, reports the acquisition of stock options.
Summary
- On January 12, 2024, Zoran Zdraveski, Chief Legal and Strategy Officer of TScan Therapeutics, acquired stock options for 52,500 shares.
- These options vest 25% on the one-year anniversary of the grant date, with the remainder vesting monthly over the following 36 months.
- On January 3, 2025, Zdraveski acquired additional stock options for 250,000 shares, vesting 25% on the one-year anniversary of the grant date, with the remainder vesting monthly over the following 36 months.
- The exercise price for the first grant is $6, and the exercise price for the second grant is $3.065.
- The expiration dates for the options are January 12, 2034, and January 3, 2035, respectively.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future, but it also represents potential future dilution for existing shareholders.
Positives
- The granting of stock options to a key executive aligns their interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. These grants are typically subject to vesting schedules to encourage long-term commitment.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Vesting schedules, such as the one described (25% after one year, then monthly), are typical to ensure retention and performance alignment.
- Comparable companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) used similar stock option plans to incentivize their leadership teams.
Stakeholder Impact
- Shareholders may experience dilution if the options are exercised.
- Employees may be motivated by the executive's alignment with company success.
Key Dates
| Date | Description |
|---|---|
| 01/12/2024 | Grant date of stock options for 52,500 shares. |
| 01/12/2034 | Expiration date of stock options for 52,500 shares. |
| 01/03/2025 | Grant date of stock options for 250,000 shares. |
| 01/03/2035 | Expiration date of stock options for 250,000 shares. |
| 02/11/2025 | Date of Form 4 filing. |
Keywords
stock options, TScan Therapeutics, Zoran Zdraveski, executive compensation, Form 4, insider trading, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.